## CONTENTS

### SPECIAL SECTION ON DRUG METABOLISM AND THE MICROBIOME

**Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?**

Hollie I. Swanson ......................................................... 1499

Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids.

Curtis D. Klaassen and Julia Yue Cui .............................. 1505

Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation.

Troy D. Hubbard, Iain A. Murray, and Gary H. Perdew .............. 1522

Aryl Hydrocarbon Receptor Activity of Tryptophan Metabolites in Young Adult Mouse Colonocytes.


Importance of Large Intestine in Regulating Bile Acids and Glucagon-Like Peptide-1 in Germ-Free Mice.

Felcy Pavithra Selwyn, Iván L. Csanaky, Youcai Zhang, and Curtis D. Klaassen. ................................. 1544

Microbiome Disturbances and Autism Spectrum Disorders.

Cheryl S. Rosenfeld ......................................................... 1557

**RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice.**

Felcy Pavithra Selwyn, Julia Yue Cui, and Curtis D. Klaassen ................................. 1572

**Gut Microbiota-Mediated Drug-Antibiotic Interactions.**

Dong-Hyun Kim ............................................................ 1581

**Intestinal Absorption and Metabolism of Epimedium Flavonoids in Osteoporosis Rats.**

Jing Zhou, Yi Hua Ma, Zhong Zhou, Yan Chen, Ying Wang, and Xia Gao ......................................................... 1590

**The Presystemic Interplay between Gut Microbiota and Orally Administered Calycosin-7-O-β-d-Glucoside.**

Jian-Qing Ruan, Shang Li, Ya-Ping Li, Wen-Jin Wu, Simon Ming-Yuen Lee, and Ru Yan ......................................................... 1601

### SHORT COMMUNICATION

**Making Transporter Models for Drug–Drug Interaction Prediction Mobile.**

Sean Ekins, Alex M. Clark, and Stephen H. Wright ................. 1642

### ARTICLES

**Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies.**

Michelle McCabe, Rucha S. Sane, Monica Keith-Luzzi, Jun Xu, Illeaniz King, Andrea Withercher-Johnstone, Nicholas Johnstone, Donald J. Tweedie, and Yongmei Li ........................................... 1612

**Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome.**

Lian Yee Yip and Eric Chun Yong Chan ........................................... 1619

**Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole.**

Shotaro Uehara, Jun Xu, Takashi Inoue, Mirai Kawano, Makiko Shimizu, Akiko Toda, Masahiro Utai, Erika Sasaki, and Hiroshi Yamazaki ........................................... 1408

**Prediction of Drug–Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.**

Shinji Yamazaki, Theodore R. Johnson, and Bill J. Smith ........... 1417

**Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfortransferase 1A3–Overexpressing Human Embryonic Kidney 293 Cells.**

Hua Sun, Xiao Wang, Xiaotong Zhou, Danyi Lu, Zhiguo Ma, and Baqian Wu ........................................... 1430

**Lipid Peroxide–Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples.**

Chungang Gu, Richard J. Lewis, Andrew S. Wells, Per H. Svensson, Vinayak P. Hosagraghara, Eskil Johnsson, and Gösta Hallström ........................................... 1441
Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: A representation of the emerging interplay that exists between the gut microbiota and liver in mediating drug metabolism. Lower left image by N.R. Fuller of Sayo-Art LLC. Digestive system image by Alena Hovorkova/Shutterstock.com.